10-Q · May 11, 2026
Erasca reported a significant net loss of $183.4 million in Q1 2026, substantially widening from a loss of $31.0 million in Q1 2025, primarily driven by a $150 million charge for in-process research and development.…
Earnings analysis · 10-Q
ERAS earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the financial statements or MD&A needed to assess revenue, margins, EPS, segment performance, balance-sheet changes, or cash flow, so those metrics are left null. Disclosure…
Read full summary
The supplied 10-Q excerpt does not include the financial statements or MD&A needed to assess revenue, margins, EPS, segment performance, balance-sheet changes, or cash flow, so those metrics are left null. Disclosure controls were deemed effective as of June 30, 2026, and management reported no material market-risk changes. However, the filing adds material legal risks involving ERAS-0015 intellectual property claims and securities-related litigation, including a derivative complaint filed in August 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Remained Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026. The company also reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No Material Market-Risk Changes
As of June 30, 2026, management reported no material changes in market risk from the 2025 Form 10-K across interest-rate risk, foreign-currency risk, and inflation risk.
What to watch
-
ERAS-0015 IP Dispute
On April 24, 2026, Revolution Medicines alleged that ERAS-0015 infringes U.S. Patent No. 12,409,225 and raised trade-secret and comparative-disclosure claims. Potential remedies include injunctive relief, monetary damages, licensing requirements, or changes to development and commercialization plans.
-
Securities Class-Action Litigation
A purported securities class action was filed on June 10, 2026, against Erasca and certain officers in the Southern District of California. The complaint seeks damages, costs, and other unspecified relief, and could increase legal expenses and divert management attention.
-
Derivative Complaint Adds Legal Risk
In August 2026, a stockholder derivative complaint was filed against the company as nominal defendant and certain directors and officers, alleging fiduciary-duty breaches and Exchange Act Section 14(a) violations related to ERAS-0015 disclosures. The company stated that the matter is at an early stage and that it cannot estimate a possible loss or range of loss.
Management's outlook
No quantitative revenue or EPS guidance is provided in the supplied 10-Q excerpt. The filing discusses no change to market-risk disclosures as of June 30, 2026, but does not provide a numeric operating outlook.
Earlier filings 4
10-K · March 12, 2026
Erasca positions itself as a modality-agnostic, RAS/MAPK-focused precision oncology company with two clinical-stage RAS programs (ERAS-0015 and ERAS-4001) and a discovery-stage EGFR biparatopic antibody (ERAS-12). The…
10-Q · November 12, 2025
Erasca remains a pre-revenue clinical‑stage company with a modest quarter-to-quarter improvement in operating loss driven by lower R&D spending. For the three months ended September 30, 2025 the company reported a net…
10-Q · August 12, 2025
Erasca reported a materially narrower Q2 2025 operating loss driven by lower operating expenses: total operating expenses fell to $38,125 (Q2 2025) from $67,782 (Q2 2024), producing a net loss of $33,876 and diluted…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.